Drug Profile
Tetrahydrocannabivarin 9 - GW Pharmaceuticals
Alternative Names: Delta-9-tetrahydrocannabivarin; GW-42004; GWP-42004; Tetrahydrocannabivarol; THCVLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Class Antihyperglycaemics; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Romania (PO)
- 27 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in United Kingdom (PO)
- 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc